ArticleBlood advances2022

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.

Anastasios Stathis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.